Multiple law firms filed a securities class-action lawsuit against Regeneron Pharmaceuticals on August 10, 2026.
The lawsuit represents investors who purchased shares between August 1, 2025, and May 15, 2026.
The complaint alleges Regeneron made misleading statements regarding its Phase 3 trial of Fianlimab for melanoma.
Plaintiffs claim the company failed to disclose fundamental flaws in its statistical assumptions.
The drug reportedly lacked meaningful clinical differentiation and failed to meet its primary endpoint.
Regeneron's stock price dropped significantly following the trial results in May 2026.